Ebola Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.Anti-spam check. Do not fill this in! ==Research== ===Treatments=== {{Main|Ebola virus disease treatment research}} [[File:monoclonal antibodies3.jpg|thumb|Researchers looking at slides of cultures of cells that make [[monoclonal antibodies]]. These are grown in a lab and the researchers are analyzing the products to select the most promising.]] {{As of|2015|7}}, no medication has been proven safe and effective for treating Ebola. By the time the [[Ebola virus epidemic in West Africa]] began in 2013, there were at least nine different candidate treatments. Several trials were conducted in late 2014, and early 2015, but some were abandoned due to lack of efficacy or lack of people to study.<ref>{{Cite web |title=Final trial results confirm Ebola vaccine provides high protection against disease |url=https://www.who.int/mediacentre/news/releases/2016/ebola-vaccine-results/en/ |url-status=live |archive-url=https://web.archive.org/web/20170401042946/http://who.int/mediacentre/news/releases/2016/ebola-vaccine-results/en/ |archive-date=1 April 2017 |access-date=29 March 2017 |publisher=[[World Health Organization]] (WHO)}}</ref> {{As of|2019|8}}, two experimental treatments known as [[atoltivimab/maftivimab/odesivimab]] and [[ansuvimab]] were found to be 90% effective.<ref>{{Cite journal |vauthors=Maxmen A |date=12 August 2019 |title=Two Ebola drugs show promise amid ongoing outbreak |journal=Nature |doi=10.1038/d41586-019-02442-6 |issn=0028-0836 |pmid=32778704 |s2cid=201975390}}</ref><ref>{{Cite journal |vauthors=Hoenen T, Groseth A, Feldmann H |date=24 July 2019 |title=Therapeutic strategies to target the Ebola virus life cycle |journal=Nature Reviews. Microbiology |volume=17 |issue=10 |pages=593–606 |doi=10.1038/s41579-019-0233-2 |issn=1740-1526 |pmid=31341272 |doi-access=free}}</ref><ref>{{Cite press release |title=Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults |date=24 January 2019 |publisher=[[National Institute of Allergy and Infectious Diseases]] (NIAID) |url=https://www.niaid.nih.gov/news-events/investigational-monoclonal-antibody-treat-ebola-safe-adults |access-date=12 August 2019}}</ref> ===Diagnostic tests=== The diagnostic tests currently available require specialised equipment and highly trained personnel. Since there are few suitable testing centres in West Africa, this leads to delay in diagnosis.<ref>{{Cite magazine | vauthors = Butler D |title=Ebola Experts Seek to Expand Testing |url=http://www.scientificamerican.com/article/ebola-experts-seek-to-expand-testing/ |url-status=live |magazine=[[Scientific American]] |archive-url=https://web.archive.org/web/20141213012943/http://www.scientificamerican.com/article/ebola-experts-seek-to-expand-testing/ |archive-date=13 December 2014 |access-date=11 December 2014}}</ref> On 29 November 2014, a new 15-minute Ebola test was reported that if successful, "not only gives patients a better chance of survival, but it prevents transmission of the virus to other people." The new equipment, about the size of a laptop and solar-powered, allows testing to be done in remote areas.<ref>{{Cite news | vauthors = Buchanan RT |date=29 November 2014 |title=Ebola outbreak: New 15-minute test offers hope for thousands |work=The Independent |url=https://www.independent.co.uk/news/world/africa/ebola-outbreak-new-15minute-test-trialled-in-guinea-offers-hope-for-thousands-9892543.html |url-status=live |access-date=1 December 2014 |archive-url=https://web.archive.org/web/20141201003020/http://www.independent.co.uk/news/world/africa/ebola-outbreak-new-15minute-test-trialled-in-guinea-offers-hope-for-thousands-9892543.html |archive-date=1 December 2014}}</ref> On 29 December 2014, the U.S. [[Food and Drug Administration]] (FDA) approved the LightMix Ebola Zaire [[Reverse transcription polymerase chain reaction|rRT-PCR]] test for patients with symptoms of Ebola.<ref>{{Cite news | vauthors = Falconi M |date=29 December 2014 |title=Roche Secures Emergency Approval by U.S. Regulators for Ebola Test |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/roche-secures-emergency-approval-by-u-s-regulators-for-ebola-test-1419840858 |url-status=live |url-access=subscription |access-date=29 December 2014 |archive-url=https://web.archive.org/web/20141229163045/http://www.wsj.com/articles/roche-secures-emergency-approval-by-u-s-regulators-for-ebola-test-1419840858 |archive-date=29 December 2014}}</ref> ===Disease models=== Animal models and in particular non-human primates are being used to study different aspects of Ebola virus disease. Developments in [[organ-on-a-chip]] technology have led to a chip-based model for Ebola haemorrhagic syndrome.<ref>{{cite journal | vauthors = Junaid A, Tang H, van Reeuwijk A, Abouleila Y, Wuelfroth P, van Duinen V, Stam W, van Zonneveld AJ, Hankemeier T, Mashaghi A | display-authors = 6 | title = Ebola Hemorrhagic Shock Syndrome-on-a-Chip | journal = iScience | volume = 23 | issue = 1 | pages = 100765 | date = January 2020 | pmid = 31887664 | pmc = 6941864 | doi = 10.1016/j.isci.2019.100765 | bibcode = 2020iSci...23j0765J }}</ref> Summary: Please note that all contributions to Christianpedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here. You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Christianpedia:Copyrights for details). Do not submit copyrighted work without permission! Cancel Editing help (opens in new window) Discuss this page